Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-211-H
- Development stage
- Phase 1
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AD-211-H** is an oral, dose-specific investigational formulation of **celecoxib + eperisone** being developed by Addpharma for symptomatic treatment of knee osteoarthritis. Celecoxib is a selective cyclooxygenase-2 inhibitor that reduces inflammatory prostaglandin production, while eperisone is a centrally acting skeletal-muscle relaxant that inhibits voltage-gated sodium and calcium channels, reducing spinal reflex activity and muscle hypertonia. AD-211-H is being evaluated as one of several AD-211 dose formulations in a randomized Phase 2 dose-optimization study in patients with osteoarthritis of the knee.
- Other names
- celecoxib + eperisone
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on AD-211-H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-211-H.